Marc Tessier-Lavigne - 21 Mar 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**Marc Tessier-Lavigne
Issuer symbol
REGN
Transactions as of
21 Mar 2022
Transactions value $
-$2,299,023
Form type
4
Date filed
23 Mar 2022, 16:01
Previous filing
18 Mar 2022
Next filing
28 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $2.83M +7.44K +327.85% $380.95 9.71K 21 Mar 2022 Direct F1
transaction REGN Common Stock Sale -$5.13M -7.44K -76.63% $690.00 2.27K 21 Mar 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -7.44K -100% $0.00* 0 21 Mar 2022 Common Stock 7.44K $380.95 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.